The latest price target for AtriCure (NASDAQ:ATRC) was reported by Canaccord Genuity on February 18, 2026. The analyst firm set a price target for $53.00 expecting ATRC to rise to within 12 months (a possible 78.48% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for AtriCure (NASDAQ:ATRC) was provided by Canaccord Genuity, and AtriCure maintained their buy rating.

The last upgrade for AtriCure Inc happened on April 23, 2024 when Oppenheimer raised their price target to $32. Oppenheimer previously had a perform for AtriCure Inc.

The last downgrade for AtriCure Inc happened on February 18, 2026 when Oppenheimer changed their price target from N/A to N/A for AtriCure Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AtriCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AtriCure was filed on February 18, 2026 so you should expect the next rating to be made available sometime around February 18, 2027.

While ratings are subjective and will change, the latest AtriCure (ATRC) rating was a maintained with a price target of $64.00 to $53.00. The current price AtriCure (ATRC) is trading at is $29.69, which is out of the analyst’s predicted range.